{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T08:32:04Z","timestamp":1786609924131,"version":"build-2736575974"},"reference-count":34,"publisher":"MDPI AG","issue":"16","license":[{"start":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T00:00:00Z","timestamp":1786579200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Background and Objectives: The outcomes for patients with localised prostate cancer are variable, even within defined tumour grades or clinical risk groups. Identifying features associated with disease aggression is imperative in contemporary PCa research. ISUP 2 PCa is particularly important in this regard as it exhibits a wide range of oncologic behaviour. The aim of this study was to evaluate the relationship between the tumour volume at radical prostatectomy (RP) and metastasis-free survival (MFS) in patients with ISUP 2 PCa. Methods: In this longitudinal multicentre cohort study, we reviewed the data of 809 consecutive patients with ISUP 2 PCa who underwent RP between 1996 and 2021. The tumour volume was estimated by summing the visual percentage involvement and multiplying it by specimen weight. Kaplan\u2013Meier and Cox regression models were used to assess MFS. Linear regression was used to identify the preoperative predictors of the tumour volume (TV), with the appropriate assumption checks. Key Findings: The median TV was 2.9 cc (IQR: 1.4\u20137.0 cc). The TV categories were &lt;2 cc (37%), 2\u201320 cc (53%), and &gt;20 cc (11%). The median PSA follow-up was 42 months; 11% experienced biochemical recurrence (BCR). The BCR rates differed significantly across volume categories (p &lt; 0.01). At 120 months, MFS was highest in the &lt;2 cc group (97%) and lowest in the &gt;20 cc group (87%) (p &lt; 0.01). Conclusions and Clinical Implications: Prostate-TV in ISUP-grade group 2 disease is independently associated with MFS. Tumours &gt; 20 cc warrant closer monitoring and may benefit from adjuvant therapy. The improved pre-operative prediction of TV could support more tailored treatment strategies, including suitability for surveillance. What does the study add? We demonstrate for first time that tumour volume at prostatectomy is correlated with metastasis-free survival in ISUP 2 PCa. At 120 months, MFS was highest in the &lt;2 cc group (97%) and lowest in the &gt;20 cc group (87%) (p &lt; 0.01). This has implications for post-operative surveillance.<\/jats:p>","DOI":"10.3390\/cancers18162605","type":"journal-article","created":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T08:06:16Z","timestamp":1786608376000},"page":"2605","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Tumour Volume Independently Predicts Metastasis in ISUP 2 Prostate Cancer"],"prefix":"10.3390","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6072-6191","authenticated-orcid":false,"given":"David","family":"Homewood","sequence":"first","affiliation":[{"name":"Department of Urology, Western Health, Melbourne 3011, Australia"},{"name":"Department of Surgery, University of Melbourne, Melbourne 3010, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7962-8201","authenticated-orcid":false,"given":"Brendan","family":"Yanada","sequence":"additional","affiliation":[{"name":"Department of Urology, Western Health, Melbourne 3011, Australia"},{"name":"Department of Surgery, University of Melbourne, Melbourne 3010, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clancy","family":"Mullholland","sequence":"additional","affiliation":[{"name":"Department of Urology, Western Health, Melbourne 3011, Australia"},{"name":"Department of Surgery, University of Melbourne, Melbourne 3010, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin","family":"Lyttwin","sequence":"additional","affiliation":[{"name":"Department of Urology, University of Bern, 3010 Bern, Switzerland"},{"name":"Department of Urology, Solothurner Spit\u00e4ler AG, Kantonsspital Olten, 4600 Solothurn, Switzerland"},{"name":"Department of Urology, Solothurner Spit\u00e4ler AG, B\u00fcrgerspital Solothurn, 4500 Solothurn, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Prabhpreet","family":"Mangat","sequence":"additional","affiliation":[{"name":"Department of Urology, Western Health, Melbourne 3011, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tanita","family":"Botha","sequence":"additional","affiliation":[{"name":"Department of Urology, Western Health, Melbourne 3011, Australia"},{"name":"Biostatistics Unit, Faculty of Health, Deakin University, Geelong 3220, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3710-014X","authenticated-orcid":false,"given":"Niranjan","family":"Sathianathen","sequence":"additional","affiliation":[{"name":"Department of Urology, Western Health, Melbourne 3011, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1908-3286","authenticated-orcid":false,"given":"George N.","family":"Thalmann","sequence":"additional","affiliation":[{"name":"Department of Urology, University of Bern, 3010 Bern, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4483-6945","authenticated-orcid":false,"given":"Niall M.","family":"Corcoran","sequence":"additional","affiliation":[{"name":"Department of Urology, Western Health, Melbourne 3011, Australia"},{"name":"Department of Surgery, University of Melbourne, Melbourne 3010, Australia"},{"name":"Department of Urology, Royal Melbourne Hospital, Melbourne 3050, Australia"},{"name":"Department of Urology, Frankston Hospital, Melbourne 3199, Australia"},{"name":"Victorian Comprehensive Cancer Centre, Melbourne 3000, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc A.","family":"Furrer","sequence":"additional","affiliation":[{"name":"Department of Urology, University of Bern, 3010 Bern, Switzerland"},{"name":"Department of Urology, Solothurner Spit\u00e4ler AG, Kantonsspital Olten, 4600 Solothurn, Switzerland"},{"name":"Department of Urology, Solothurner Spit\u00e4ler AG, B\u00fcrgerspital Solothurn, 4500 Solothurn, Switzerland"},{"name":"Department of Anaesthesiology and Pain Medicine, Inselspital, Bern University Hospital, University of Bern, 3010 Bern, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,8,13]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1016\/S0022-5347(05)67713-0","article-title":"Prostate cancer is highly predictable: A prognostic equation based on all morphological variables in radical prostatectomy specimens","volume":"163","author":"Stamey","year":"2000","journal-title":"J. Urol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1038\/modpathol.2010.156","article-title":"International Society of Urological Pathology (ISUP) Consensus Conference on Handling and Staging of Radical Prostatectomy Specimens. Working group 2: T2 substaging and prostate cancer volume","volume":"24","author":"Amin","year":"2011","journal-title":"Mod. Pathol."},{"key":"ref_3","unstructured":"EAU (2024). EAU-EANM-ESTRO-ESUR-ISUP-SIOG Guidelines on Prostate Cancer, EAU."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1111\/bju.12458","article-title":"Comparison of contemporary methods for estimating prostate tumour volume in pathological specimens","volume":"113","author":"Perera","year":"2014","journal-title":"BJU Int."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1002\/1097-0142(20000901)89:5<1056::AID-CNCR15>3.0.CO;2-U","article-title":"Assessment of morphometric measurements of prostate carcinoma volume","volume":"89","author":"Noguchi","year":"2000","journal-title":"Cancer"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.1097\/00000478-200310000-00001","article-title":"A Streamlined Three-Dimensional Volume Estimation Method Accurately Classifies Prostate Tumors by Volume","volume":"27","author":"Chen","year":"2003","journal-title":"Am. J. Surg. Pathol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1093\/ajcp\/107.6.704","article-title":"Estimation of Tumor Volume in Radical Prostatectomy Specimens in Routine Clinical Practice","volume":"107","author":"Renshaw","year":"1997","journal-title":"Am. J. Clin. Pathol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1038\/modpathol.3800405","article-title":"Maximum tumor diameter is an independent predictor of prostate-specific antigen recurrence in prostate cancer","volume":"18","author":"Eichelberger","year":"2005","journal-title":"Mod. Pathol."},{"key":"ref_9","doi-asserted-by":"crossref","unstructured":"Baba, H., Sakamoto, S., Zhao, X., Yamada, Y., Rii, J., Fujimoto, A., Kanesaka, M., Takeuchi, N., Sazuka, T., and Imamura, Y. (2022). Tumor Location and a Tumor Volume over 2.8 cc Predict the Prognosis for Japanese Localized Prostate Cancer. Cancers, 14.","DOI":"10.3390\/cancers14235823"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1038\/s41391-021-00468-4","article-title":"Is tumour volume an independent predictor of outcome after radical prostatectomy for high-risk prostate cancer?","volume":"26","author":"Raison","year":"2023","journal-title":"Prostate Cancer Prostatic Dis."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"123","DOI":"10.5534\/wjmh.2016.34.2.123","article-title":"The Effect of Tumor-Prostate Ratio on Biochemical Recurrence after Radical Prostatectomy","volume":"34","author":"Cho","year":"2016","journal-title":"World J. Mens. Health"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1786","DOI":"10.2967\/jnumed.120.242057","article-title":"Semiautomatically quantified tumor volume using 68Ga-PSMA-11 PET as a biomarker for survival in patients with advanced prostate cancer","volume":"61","author":"Seifert","year":"2020","journal-title":"J. Nucl. Med."},{"key":"ref_13","first-page":"445","article-title":"Can tumour volume percentage in radical prostatectomy predict cancer biochemical recurrence? Determining a cut-off point and composite risk factors approach","volume":"13","author":"Alenezi","year":"2021","journal-title":"Res. Rep. Urol."},{"key":"ref_14","doi-asserted-by":"crossref","unstructured":"Sathianathen, N.J., Furrer, M.A., Mulholland, C.J., Katsios, A., Soliman, C., Lawrentschuk, N., Peters, J.S., Zargar, H., Costello, A.J., and Hovens, C.M. (2024). Lymphovascular Invasion at the Time of Radical Prostatectomy Adversely Impacts Oncological Outcomes. Cancers, 16.","DOI":"10.3390\/cancers16010123"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1007\/s10147-011-0295-2","article-title":"Percent tumor volume predicts biochemical recurrence after radical prostatectomy: Multi-institutional data analysis","volume":"17","author":"Song","year":"2012","journal-title":"Int. J. Clin. Oncol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1093\/jnci\/djp122","article-title":"Risk assessment for prostate cancer metastasis and mortality at the time of diagnosis","volume":"101","author":"Cooperberg","year":"2009","journal-title":"J. Natl. Cancer Inst."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1007\/s00345-008-0242-7","article-title":"Maximum tumor diameter is not an independent prognostic factor in high-risk localized prostate cancer","volume":"26","author":"Witjes","year":"2008","journal-title":"World J. Urol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1007\/s00066-017-1140-y","article-title":"Defining biochemical recurrence after radical prostatectomy and timing of early salvage radiotherapy","volume":"193","author":"Schiffmann","year":"2017","journal-title":"Strahlenther. Und Onkol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1097\/JU.0000000000004587","article-title":"Pelvic Lymph Node Dissection in Prostate Cancer: Is It Really Necessary? A Multicentric Longitudinal Study Assessing Oncological Outcomes in Patients with Prostate Cancer Patients Undergoing Pelvic Lymph Node Dissection vs Radical Prostatectomy Only","volume":"214","author":"Furrer","year":"2025","journal-title":"J. Urol."},{"key":"ref_20","unstructured":"R Core Team (2024). R: A Language and Environment for Statistical Computing [Internet], R Foundation for Statistical Computing. Available online: https:\/\/www.R-project.org."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1097\/JU.0000000000002803","article-title":"Neoadjuvant Novel Hormonal Therapy Followed by Prostatectomy versus Up-Front Prostatectomy for High-Risk Prostate Cancer: A Comparative Analysis","volume":"208","author":"Ravi","year":"2022","journal-title":"J. Urol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1306","DOI":"10.1016\/j.eururo.2007.11.057","article-title":"Validation of the Contemporary Epstein Criteria for Insignificant Prostate Cancer in European Men","volume":"54","author":"Jeldres","year":"2008","journal-title":"Eur. Urol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1097\/JU.0000000000001389","article-title":"Predicting Pathological Tumor Size in Prostate Cancer Based on Multiparametric Prostate Magnetic Resonance Imaging and Preoperative Findings","volume":"205","author":"Pooli","year":"2021","journal-title":"J. Urol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1007\/s11934-020-00987-y","article-title":"Use of Imaging to Optimise Prostate Cancer Tumour Volume Assessment for Focal Therapy Planning","volume":"21","author":"Tam","year":"2020","journal-title":"Curr. Urol. Rep."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"847","DOI":"10.2967\/jnumed.121.262398","article-title":"Head-to-Head Comparison of 68Ga-PSMA-11 PET\/CT and mpMRI with a Histopathology Gold Standard in the Detection, Intraprostatic Localization, and Determination of Local Extension of Primary Prostate Cancer: Results from a Prospective Single-Center Imaging Trial","volume":"63","author":"Sonni","year":"2022","journal-title":"J. Nucl. Med."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1016\/j.juro.2015.04.075","article-title":"Prostate Cancer Volume Estimation by Combining Magnetic Resonance Imaging and Targeted Biopsy Proven Cancer Core Length: Correlation with Cancer Volume","volume":"194","author":"Matsugasumi","year":"2015","journal-title":"J. Urol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.euros.2022.12.002","article-title":"Prostate Cancer Tumor Volume and Genomic Risk","volume":"48","author":"Ramaswamy","year":"2023","journal-title":"Eur. Urol. Open Sci."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"e456","DOI":"10.1002\/bco2.456","article-title":"Focal therapy of prostate cancer: Use of artificial intelligence to define tumour volume and predict treatment outcomes","volume":"6","author":"Brisbane","year":"2025","journal-title":"BJUI Compass"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.eururo.2024.03.027","article-title":"EAU-EANM-ESTRO-ESUR-ISUP-SIOG Guidelines on Prostate Cancer\u20142024 Update. Part I: Screening, Diagnosis, and Local Treatment with Curative Intent","volume":"86","author":"Cornford","year":"2024","journal-title":"Eur. Urol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"253","DOI":"10.31128\/AJGP-06-23-6866","article-title":"When less is more: Updates in active surveillance and watchful waiting in the management of prostate cancer","volume":"53","author":"Homewood","year":"2024","journal-title":"Aust. J. Gen. Pract."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1038\/s41391-024-00907-y","article-title":"Identifying the best candidate for focal therapy: A comprehensive review","volume":"28","author":"Ghoreifi","year":"2024","journal-title":"Prostate Cancer Prostatic Dis."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1038\/s41698-022-00272-w","article-title":"Tumor microenvironment heterogeneity an important mediator of prostate cancer progression and therapeutic resistance","volume":"6","author":"Ge","year":"2022","journal-title":"npj Precis Oncol."},{"key":"ref_33","doi-asserted-by":"crossref","unstructured":"Testa, U., Castelli, G., and Pelosi, E. (2019). Cellular and Molecular Mechanisms Underlying Prostate Cancer Development: Therapeutic Implications. Medicines, 6.","DOI":"10.3390\/medicines6030082"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1186\/s12943-019-1089-9","article-title":"Role of hypoxia in cancer therapy by regulating the tumor microenvironment","volume":"18","author":"Jing","year":"2019","journal-title":"Mol. Cancer"}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/18\/16\/2605\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T08:26:22Z","timestamp":1786609582000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/18\/16\/2605"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,13]]},"references-count":34,"journal-issue":{"issue":"16","published-online":{"date-parts":[[2026,8]]}},"alternative-id":["cancers18162605"],"URL":"https:\/\/doi.org\/10.3390\/cancers18162605","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,13]]}}}